Your browser doesn't support javascript.
Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection.
Merz, Lauren E; Mistry, Kavita; Neuberg, Donna; Freedman, Revital; Menard, Gerda; Dorfman, David M; Park, Hae Soo; Jolley, Katherine; Achebe, Maureen O.
  • Merz LE; Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA.
  • Mistry K; Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA.
  • Neuberg D; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Freedman R; Division of Hematology, Department of Internal Medicine, and.
  • Menard G; Department of Pathology, Brigham and Women's Hospital, Boston, MA; and.
  • Dorfman DM; Department of Pathology, Brigham and Women's Hospital, Boston, MA; and.
  • Park HS; Division of Hematology, Department of Internal Medicine, and.
  • Jolley K; Division of Hematology, Department of Internal Medicine, and.
  • Achebe MO; Division of Hematology, Department of Internal Medicine, and.
Blood Adv ; 5(18): 3690-3693, 2021 09 28.
Article in English | MEDLINE | ID: covidwho-1440897
ABSTRACT
The COVID-19 pandemic has highlighted racial health disparities within the United States. Although social determinants of health are the most likely drivers of this disparity, it is possible that genetic traits enriched in the black population like sickle cell trait (SCT) could worsen the morbidity and mortality of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients admitted for SARS-CoV-2 infection who identified as black or African American were included in the study (n = 166). Blood remnants were tested for SCT, and clinical data were abstracted from the chart. There was no difference in mortality between those with SCT and those without. There was no difference in respiratory complications between groups, but those without SCT had a much higher burden of chronic lung disease (P = .004). Those with SCT had higher creatinine on admission (P = .004), but no difference in in-hospital renal complications (P = .532). Notably, 12% of the cohort had SCT, which is higher than the expected 7.31% (P = .025). Our study did not show any evidence of increased end organ damage, morbidity, or mortality from SARS-CoV-2 infection among patients with SCT but did show differences in admission creatinine and preexisting lung disease.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Sickle Cell Trait / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: North America Language: English Journal: Blood Adv Year: 2021 Document Type: Article Affiliation country: Bloodadvances.2021004977

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Sickle Cell Trait / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: North America Language: English Journal: Blood Adv Year: 2021 Document Type: Article Affiliation country: Bloodadvances.2021004977